STERIS plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $STE in the last 30 days.
See all $STE insider activity →STERIS (STE) has outperformed Abbott Laboratories (ABT) year-to-date and over the past 52 weeks. Analysts give STE a 'Moderate Buy' rating with a mean price target of $263.75, implying 25.4% upside.
Industrial SalesLeads tracked 14 chemical and industrial manufacturing projects in August, with 8 focused on chemical manufacturing. The largest project is a $600M sterilization campus in North Carolina. The American Chemistry Council reported high capital spending and record production levels despite rising costs. Projects include investments by Aternium Inc., Steris, Mitsubishi Chemical Advanced Materials, Columbus Chemical Industries, and CF Industries.
STERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning STE (STERIS plc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent STE coverage spans financial news, earnings and corporate actions.
New analyst consensus and price target may attract buying interest.
Large capital outlay signals growth for Steris' sterilization business.
Steris posted solid top‑line growth but margin compression, prompting a modest price‑target uplift.
This is a routine insider open-market sale with no 10b5-1 plan disclosed, but it does not by itself signal a fundamental change.
Guidance reaffirmation plus a large capex plan and restructuring charges can shift near-term FCF expectations and medium-term margin/capacity outlook.
AlphAI scores every news story that mentions STE with an AI model for sentiment and relevance, and aggregates insider trades from STERIS plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
STERIS (STE) has outperformed Abbott Laboratories (ABT) year-to-date and over the past 52 weeks. Analysts give STE a 'Moderate Buy' rating with a mean price target of $263.75, implying 25.4% upside.
1 min readIndustrial SalesLeads tracked 14 chemical and industrial manufacturing projects in August, with 8 focused on chemical manufacturing. The largest project is a $600M sterilization campus in North Carolina. The American Chemistry Council reported high capital spending and record production levels despite rising costs. Projects include investments by Aternium Inc., Steris, Mitsubishi Chemical Advanced Materials, Columbus Chemical Industries, and CF Industries.
2 min readSTERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.
2 min readSohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.
1 min readSTERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.
4 min readSimply Wall St reports that STERIS (STE) rose about 2.5% to $237.47 after its Q1 FY2027 results. Revenue was $1,492.7m (+7.3% YoY) and net income $200.1m (+12.8%), with EPS of $2.05. The article highlights higher margins, higher capex, and valuation concerns around a ~28.8x P/E and EPS guidance of $11.10 to $11.30.
6 min readSTERIS plc plans a $600 million manufacturing, R&D and lab facility in Sanford, North Carolina, at Helix Innovation Park. The project is expected to create 335 jobs and serve as its Chemistries Manufacturing Center of Excellence. North Carolina approved a JDIG grant, potentially reimbursing up to $3.213 million over 12 years, tied to annual performance targets.
3 min readNorth Carolina Railroad Co. and Norfolk Southern are backing a $600 million STERIS Chemistries Manufacturing Center of Excellence in Sanford, N.C. NCRR will spend up to $600,000 on rail infrastructure, enabling at least 160 railcars annually by 2031. The project is expected to create 335+ jobs, with operations starting in 2-3 years, according to company releases.
3 min readSTERIS plc (STE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2026 STERIS plc (Exact Name of Registrant as Specified
2 min readThe article is a political roundup of Democratic governors’ actions in several states. It highlights New Mexico Gov. Michelle Lujan Grisham on housing and ICE protections, New York Gov. Kathy Hochul on a data center moratorium and preschool, and North Carolina Gov. Josh Stein’s announcement that STERIS (NYSE: STE) will invest $600 million and create 335 jobs. It also cites Oregon Gov. Tina Kotek’s $10 million Regional Infrastructure Fund and a tariff impact analysis.
4 min read
%252FSteris%252520Corporation%252520logo%252520is%252520displayed%252520on%252520a%252520smartphone%252520screen_By%252520Rafael%252520Henrique.jpeg&w=384&q=75)
